Eversense 365 delivered favorable glucometrics compared to other open and closed loop systems, validating the one-year CGM’s differentiated approach and high performance New data expands on findings shared at ATTD and reinforces Eversense 365’s stron

Trade Compliance Records has published a reference on the June 3, 2026 Executive Order titled "Strengthening Customs Enforcement," which establishes a 50 percent minimum penalty floor on customs violations and directs maximum penalties for brokers wh

"Australian travel eSIM provider BazTel launches $1 for 1GB international data plans across major travel destinations to encourage eSIM adoption and provide affordable connectivity for international travelers."Sydney, Australia--(Newsfile Corp. - Jun

NEW YORK, June 06, 2026 (GLOBE NEWSWIRE) -- All In FutureTech Alliance (Nasdaq: AIFA) (“AIFA” or the “Company”) today provided a strategic update. Following the Company’s previously announced signing of agreements to acquire a controlling interest in

Arbitrum-based prediction market protocol prepares for global expansion with AI-powered market resolution, expanded liquidity infrastructure, and upcoming Version 2 releasePanama City, Panama--(Newsfile Corp. - June 6, 2026) - RAIN, the decentralized

Burlington, Ontario--(Newsfile Corp. - June 5, 2026) - Promino Nutritional Sciences, Inc. (CSE: MUSL) (OTCID: MUSLF) (FSE: 93X) ("Promino" or the "Company") announces that it has agreed to settle $373,910 in principal and accrued interest of converti

Vancouver, British Columbia--(Newsfile Corp. - June 5, 2026) - Digicann Ventures Inc. (CSE: DCNN.X) ("Digicann" or the "Company"), is a reporting issuer listed on the Canadian Securities Exchange (the "CSE"). The Company is currently focused on ident

$8.5 million upfront with up to approximately $15.2 million of potential additional gross proceeds upon the exercise in full of warrants Net proceeds anticipated to extend cash runway into first quarter of 2027, beyond expected FDA submission; if war

Builds on recent FDA approval (May 29, 2026) of Afrezza for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetesNew data and real-world findings further emphasize pediatric safety, glycemic control and treatment sat

Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as a once-weekly injection and a once-daily oral pill for the treatment of obesity and overweightAdditional data from Phase 2 obesity clinic